neuro-oncology in ayas joint efforts are worthwhile…… · medullo et pnet gliomes tgm...
TRANSCRIPT
Neuro-oncology in AYAsJoint efforts are worthwhile……
Didier FRAPPAZ
Centre Léon Bérard, and IHOP Lyon, France
PLAN
• Epidemiology
• The patients
• The tumors
• Toxicity
• Compliance
• Strategies
• Multidisciplinary meetings…….
EPIDEMIOLOGY
From: American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012Neuro Oncol. 2015;18(suppl_1):i1-i50. doi:10.1093/neuonc/nov297
Neuro Oncol | © The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail:
INCIDENCE/100,000
LAUSANNE-ANOCEF-
16.05.2014
EPIDEMIOLOGY
US cancer incidence from Surveillance, Epidemiology, and End Results
(SEER), 1975 to 1998, by CNS tumor type.Kieran M W et al. JCO 2010
8 %
6 %
19 %
64 %
THE PATIENTS
Misleading symptomsPineal Suprasellar Bifocal
11 pts 12 pts 17 pts
(10 G) (8 F) (12 G)
DUREE DES SYMTOMES 4 mths 24 mths 36 mths
Raised intracranial Pressure 100 % 46 % 39 %
Convulsions 9 % 8 % 5 %
ENDOCRINO
• Db Insipididus 9 % 62 % 100 %
• Growth delay 0 % 38 % 50 %
• precocious puberty 0 0 17 %
VISUAL
• Vision (diplopia, VF, VA) 55 % 54 % 22 %
• Parinaud 36 0 5
HYPOTHALAMIC Synd
• Frontal Synd 0 31 % 11 %
• Anorexia 0 38 % 28 %
• Memory 9 % 31 % 28 %
HARDENBERG IJROBP 1997 39:419-26
Gogtay PNAS 2004
Evolution of Gray matter
Hormonal changes
Seric hormonal levels during infancy to adulthood (Ua= arbitrary units)
BOYS GIRLS
Coincidence???…
THE TUMORS
Vadgaonkar CNS 2018
Type oftumour
Zhang et al., Nat Gen 2013
Médullo
KW. Pajtler, Cancer Cell 2015
EPendymomas
Pediatric brain tumors ≠ adult tumors
MEDULLOBLASTOMA
WHAT IS KNOWN?
Epidemiology
Biology
Optimal treatment
Long term side effects
+
+
+
+
+
+/-
?
?
Children Adults
Epidemiology
Children Adults
% of brain tumors 20% 1%0.5/106 adults
% Posterior fossa
Tumors40% 6%
WHO 2007 classification
Extensive Desmoplastic/ Classic Anaplastic, Large cell nodularity, nodular Anaplastic
Aggressivity
INFANTS CHILDREN ADULTS
10q-
TAYLOR 2012
4
3
SHIH JCO 2014Intra nuclear beta cathenin +
The tools are similar
Surgery
Increased Cranial Pressure
=> Shunt
MRI Brain and spine
SURGERY
Post op MRI 24 – 72 h
Lumbar CSF (cytospin) day 10-15
RESIDUE > 1,5 cm²And/or
CSF and/or spine +
High risk
RESIDUE < 1,5 cm²and
CSF and SPINE -
Standard risk*CCG 921 : Zeltzer (JCO 1999, 832)
Defining Clinical risk factors
36 Gy
54 Gy
36 Gy
Standard = Cranio-Spinal Irradiation
A
BC
D
EF
G
H
I
IQ loss due to supra tentorial RT
>7
Year
<7
Year
Mulhern J Clin Oncol 2OO5, 23:5511-5519.
CSI 23 Gy CSI 36-39 Gy
(- 0.42
/year)
(- 2.41
/year,
P .05
(- 1.56
/year)
(- 3.71
/year,
P .01
Chemotherapy
Clinical Experience
Standard RiskChildren
PNET 4
Surgery Randomisation
start RT < J 40
Chemo
CCNU, Cisplatin,
Vincristine
8 Cycles
HF RT1.0 Gy x 2
36/60/68/36 Gy
+ Vcr
St RT
1.8 Gy x 1
23.4/54/23.4 Gy
+ Vcr
PNET 4
n Deaths
340 47
67 events: 66 relapses 1 death CCR
First relapse + 2 months Latest relapse at + 5.5 year
7 Year EFS 0.79± 0.04 (HFRT)7 Year EFS 0.76± 0.04 (Standard RT)
p=0.82
7 Year OS 0.82±0.03
NEXT STEPLow
risk
Standard
risk
High
risk
Large Cell/
Anapastic - - +
Residue/
Metastasis< 1.5 cm2 < 1.5 cm2 > 1.5 cm2
MYC - - +
β-catenin (WNT) + - +/-
StrategyDecrease
treatment
(except if >16)
Standard
treatmentIncrease
treatment
Clinical Experience
Standard riskAdults
Bologna 1989 to 2009 95 pts
36Gy + 18 Gy to tumor bedRT
ANOCEF 1990 and November 2001, 46 pts
STANDARD RISK ADULTS
Courtesy Alba Brandes
Courtesy Luc Talliandier
5y PFS 10y EFS
52% 46%
SCHÉMA DE TRAITEMENT
2 courses chemo
(Carbo AUC 5 D1
etoposide 100 mg/m2 d 1-3)
PROSPECTIVE ANOCEF RSMA
PI: Luc Taillandier
CT RT CT
Radiotherapy before day 80
24 Gy axis + 54 Gy tumor bed
2 courses of chemotherapy
2/3 dose
Clinical ExperienceHigh RiskChildren
High dose chemo: PNET HR +5
B
I
O
P
S
I
E
+/-
E
X
E
R
E
S
E
VP
CBP
HDThiotepa
HDThiotepa
E
X
E
R
E
S
E
R
A
D
I
O
T
H
E
R
A
P
Y
36Gy
CSP
VP
CBP
CSP
Cytapheresis
E
X
E
R
E
S
E
IRM IRMIRM
2 cyclesTMZ
2 cyclesTMZ
2 cyclesTMZ
IRM IRM IRM
64 patients (MB=51; sPNET=13) from 2009 to 2012, 3 year Follow-up
3-year PFS 80%, 3-year OS 85%
Dufour, SFCE
Tarbell JCO 2013
INCREASING DOSE OF CSI
Clinical ExperienceHigh Risk
Adults
Bologna 1989 to 2009 95 pts
ANOCEF 1990 and November 2001, 46 pts
Courtesy Alba Brandes
Courtesy Luc Talliandier
CT RT CT
High RISK ADULTS
DEC Cisplatin 80 to 100 mg/m2-
Etoposide 100 to 200 mg/m2
Cyclophosphamide 600 to 1000 mg/m2
Or CBDCA AUC 5
Etoposide 300 mg/m2
Or MOPP
5y EFS 10y EFS
50% 36%
36Gy + 18 Gy to tumor bed
Beware ofTOXICITY
FEASIBILITY/TOXICITYCDDP/Lomustine/VCR
95 courses
Children
(5-10)
142 courses
Adolescents
(10-20)
p
Dose
Reduction24% 56% 0.02
Delayed
Chemo3% 23% 0.0003
Tabori Cancer, 2005, 1874
Beier JNO 2018
Adaptations required
IQ loss due to supra tentorial RT
>7
Year
<7
Year
Mulhern J Clin Oncol 2OO5, 23:5511-5519.
CSI 23 Gy CSI 36-39 Gy
(- 0.42
/year)
(- 2.41
/year,
P .05
(- 1.56
/year)
(- 3.71
/year,
P .01
Fig 1 Modification of professional status according to the (from treatment) and CSA doses.
Loss of employment
SUNYACH Communication personnelle
< 30,6Gy
> 30,6Gy
Delayed endocrinological toxicity in pediatric population
ACTH deficiency : 38+/-6%
TSH deficiency : 23+/-8% (11% if <42 Gy vs 44% if> 42 Gy: p
0.014)
GH Deficiency: 93+/-4%
Primary Thyroid deficiency : 65+/-7% (54% if <42 Gy vs 89% if> 42 Gy: p
0.017)
Laughton, JCO 2008, 1112
Hypothyroidism
Children Adults
Central TSH deficiency 0% 26%
Peripheral SCH 43% 0%
Second malignancies?.
Broniscer Cancer 2004
Relapses
Smoll (SEER) cancer 2011
Long term differs?
Anti SHH:
One impressive response in adult medulloblastoma
Converging?
R
Modified NOA-07* (see page 2)
SHH M0 (p53wt) (postpub.)
Modified NOA-07 ,with radiotherapy* dose reduction (CSI 23,4 Gy)
and LDE225 200 mg OD daily or with drug holidays
Stan
dar
d
arm
Exp
eri
me
nta
l ar
m
WNT M0 (18+)Modified NOA-07 ,with radiotherapy* dose reduction (CSI 23,4 Gy)
n=90
n=90
15%
60%
15% n=24
n=13
Group 4 M0 (18+)
Modified NOA-07 ,with radiotherapy* dose reduction (CSI 23,4 Gy)
WNT M0 (18+)SHH M0 (p53wt) (postpub.)Group 4 M0 (18+)
Inte
rme
dia
te-r
isk
pat
ien
ts
GLIOMAS
ADULT HIGH GRADE GLIOMAS
Though different…..
HERBY
BEV, bevacizumab; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; RT, radiotherapy; TMZ, temozolomide
Pediatric High grade gliomas
EFS rates (central review; secondary endpoints)
RT/TMZ (n=59) BEV + RT/TMZ (n=62)
6-month EFS rate (95% CI) 66% (53–77) 68% (55–79)
1-year EFS rate (95% CI) 48% (35–61) 38% (26–51)
8.2 months(95% CI 7.8–12.7)
11.8 months(95% CI 7.9–16.4)
Stratified HR 1.44 (95% CI 0.90–2.30) p=0.13 (log-rank test)
BEV + RT/TMZ (n=62)RT/TMZ (n=59)
Time (months)
0
100
0 6 12 18 24 30 36 42
20
40
60
80
Pro
ba
bilit
y o
f E
FS
(%
)
48
RT/TMZ
BEV + RT/TMZ
No. at risk
59 37 26 16 9 6 2 242 32 21 14 7 4 2 2
62 40 20 12 7 5 1 153 29 18 8 6 2 1 1
BRAIN STEM GLIOMAS
DIPG biopsies
Roujeau T, Machado G, Garnett MR, et al. Stereotactic biopsy of
diffuse pontine lesions in children. J Neurosurg. 2007
DIPG biology
EGFR (amp): 40% DIPG
mTO
R
erlotinib dasatinib
everolimus
MET inhibitor, crizotinib
nimotuzumab
PTEN loss: 60% DIPG
GERM CELL TUMORS
Pineal+/- supra sellar
GERMINOMAS
Calaminus Neurooncol 2013
EFS Pts Prot. Germinomas
0 12 24 36 48 60 72 84mois
0
0,2
0,4
0,6
0,8
1p
option A (CSI)
option B (CT+focal)
0.85±0.06
0.93±0.04
(CR 109/113)
(CR 45/51)
p=0.03
**
*
Cumulative Recruitement
Age French patients GCTII
0
2
4
6
8
10
12
14
<14 14-18 19-25 >26
Converging?
WEB CONFERENCE AYAEach Monday….
2016185 presentations
0
20
40
60
80
100
120
MEDULLO ET PNET GLIOMES TGM EPENDYMOMES PINEALE NF1 MOELLE TRONCS
185 presentations of 145 patients
0
10
20
30
40
50
60
70
1ere intention 2 ieme intention 1ere=> puis à la rechute
1 fois
2fois
3fois
4fois
1rst Line 2nd Line 1rst => Further Line
once
Twice
Three T
Four T
Ages
0
2
4
6
8
10
12
14
20-30 Yr 30-40 Yr > 40 Yr
Age of patientsaccording to type of tumor
Mean Median Younguest Oldest
Medulloblastoma 31 29 16 64
Germ cell Tumor 23 22 7 47
Ependymoma 35 30 4 75
Pineal 43 19 18 87
PNET 37 29 17 73
Low grade Glioma 30 26 17 55
High Grade Glioma 27 22 15 60
Else 30 24 9 57
Inot documented 34 29 10 62
SPECIALISTS
0
2
4
6
8
10
12
14
16 CHIR
ONCO
PED
ANAPATH
NEURO ONCO
ONCO
RT
CONCLUSIONS
Inclusion ages
Fern 2014 Lancet Oncol
TGM SIOP GCTII (any age)
BIOMEDE (- months-25 Year)
PersoMed (Pubertal Bone age-…….
A multidiciplinary team
• A Pathologist up to date• A Molecular biologist • A surgeon used to « travel » in the PF• A radiotherapist used to CSI• An oncologists used to toxicities• An endocrinologist• A Quos specialist• A neurologist• Pediatric with adult multidisciplinary discussion
? Dedicated Units???Long term Follow-up of chronic sequelae..